Source link : https://www.newshealth.biz/health-news/anti-tigit-shows-promise-in-unresectable-liver-cancer/
Addition of the anti-TIGIT monoclonal antibody tiragolumab to standard first-line treatment resulted in better response rates and improved survival for patients with unresectable hepatocellular carcinoma, a randomized phase Ib-II MORPHEUS-Liver study showed. At the clinical cutoff date, the 41 patients assigned to treatment with tiragolumab had a confirmed objective response rate of 43% compared with […]
Author : News Health
Publish date : 2025-01-22 21:19:28
Copyright for syndicated content belongs to the linked Source.